Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Spironolactone in Anti-VEGF Refractory nAMD
NCT03744767Phase 2Completed
- Start
- Sep 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of spironolactone in neovascular age-related macular degeneration (NVAMD). Started Sep 2014; status: completed.
02
Drugs
spironolactone
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03744767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744767.